Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts
暂无分享,去创建一个
R. Barker | J. Klein | D. Burn | Y. Ben-Shlomo | T. Foltynie | F. Baig | H. Morris | M. Hu | T. Barber | M. Tan | D. Grosset | K. Grosset | M. Lawton | S. Evetts | N. Wood | N. Malek | N. Williams | Stephanie Millin | Samuel G. Evetts | Thomas R. Barber | M. Tan | R. Barker
[1] W. Heiser,et al. The identification of Parkinson's disease subtypes using cluster analysis: A systematic review , 2010, Movement disorders : official journal of the Movement Disorder Society.
[2] M. Nalls,et al. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson’s Disease , 2020, medRxiv.
[3] R. Barker,et al. Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.
[4] P. Visscher,et al. 10 Years of GWAS Discovery: Biology, Function, and Translation. , 2017, American journal of human genetics.
[5] M. Ban,et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. , 2013, Brain : a journal of neurology.
[6] G. Plazzi,et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies , 2021, Brain : a journal of neurology.
[7] Y. Ben-Shlomo,et al. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort , 2019, Movement disorders : official journal of the Movement Disorder Society.
[8] K. Marder,et al. Cognitive performance of GBA mutation carriers with early-onset PD , 2012, Neurology.
[9] J. Jankovic,et al. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. , 2019, Parkinsonism & related disorders.
[10] Sonja W. Scholz,et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases , 2017, Neurobiology of Aging.
[11] K. Dujardin,et al. Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations , 2021, Journal of Parkinson's disease.
[12] P. Mazzoni,et al. Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.
[13] T. Perneger. What's wrong with Bonferroni adjustments , 1998, BMJ.
[14] M. Okun,et al. Parkinson's disease motor subtype changes during 20 years of follow-up. , 2020, Parkinsonism & related disorders.
[15] R. Barker,et al. Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[16] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[17] Erdogan Taskesen,et al. Functional mapping and annotation of genetic associations with FUMA , 2017, Nature Communications.
[18] D. Hernandez,et al. Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes , 2021, Neurology: Genetics.
[19] Ashley R. Jones,et al. Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases , 2018, Molecular Neurodegeneration.
[20] Y. Ben-Shlomo,et al. Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort , 2015, Journal of Parkinson's disease.
[21] Tangchun Wu,et al. Functional Variant in the SLC22A3-LPAL2-LPA Gene Cluster Contributes to the Severity of Coronary Artery Disease , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[22] E. Tolosa,et al. Motor and nonmotor heterogeneity of LRRK2‐related and idiopathic Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[23] A. Schapira,et al. Exploring the Genotype–Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers , 2021, Frontiers in Neurology.
[24] J. Jankovic,et al. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. , 2019, Parkinsonism & related disorders.
[25] M. Albert,et al. Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. , 2016, JAMA neurology.
[26] Ze-Min Fang,et al. Histone methyltransferase SMYD2: ubiquitous regulator of disease , 2019, Clinical Epigenetics.
[27] N. Lazar,et al. The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .
[28] Sonja W. Scholz,et al. A genome-wide association study in multiple system atrophy , 2016, Neurology.
[29] J. C. Cooke Bailey,et al. Genetic Risk Scores , 2016, Current protocols in human genetics.
[30] K. Marder,et al. Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.
[31] Ross M. Fraser,et al. Genetic studies of body mass index yield new insights for obesity biology , 2015, Nature.
[32] Sonja W. Scholz,et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.
[33] Genetics of 35 blood and urine biomarkers in the UK Biobank , 2020, Nature genetics.
[34] Sina A. Gharib,et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression , 2021, Nature Genetics.
[35] R. Barker,et al. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study , 2019, Brain : a journal of neurology.
[36] William J. Astle,et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases , 2020, Cell.
[37] H. Sagar,et al. A data‐driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes , 1999, Movement disorders : official journal of the Movement Disorder Society.
[38] J. Zarranz,et al. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene. , 2015, Parkinsonism & related disorders.
[39] Jonathan A C Sterne,et al. Sifting the evidence—what's wrong with significance tests? , 2001, BMJ : British Medical Journal.
[40] Genetic,et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.
[41] J. Jankovic,et al. Variable expression of Parkinson's disease , 1990, Neurology.
[42] J. Hardy,et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course , 2012, Movement disorders : official journal of the Movement Disorder Society.
[43] J. Jankovic,et al. Parkinson disease subtypes. , 2014, JAMA neurology.
[44] R. Barker,et al. Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's , 2016, Annals of neurology.
[45] J. Klein,et al. Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder , 2017, Sleep.
[46] Benjamin J. Wright,et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease , 2009, Nature Genetics.
[47] R. Barker,et al. Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[48] Sonja W. Scholz,et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture , 2020, bioRxiv.
[49] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[50] E. Friedman,et al. Motor progression of Parkinson's disease with the leucine‐rich repeat kinase 2 G2019S mutation , 2014, Movement disorders : official journal of the Movement Disorder Society.